SCHEMBL29566810

SCHEMBL29566810

CNC(=O)c1cccc(Oc2nc(NS(=O)(=O)c3cnn(C)c3)nc(-c3ccccc3C)c2C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 6/20 0.40
▸ EGFR P00533 3/20 0.40
▸ KDR P35968 3/20 0.40
▸ F10 P00742 2/20 0.40
▸ ULK1 O75385 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ FGFR3 P22607 3/20 0.37
▸ CCR2 P41597 3/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ KIT P10721 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ F2 P00734 1/20 0.35
▸ PTK2 Q05397 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ AXL P30530 1/20 0.34
▸ TYRO3 Q06418 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309919 1.00 FGFR1 (0.40) FGFR1EGFRKDRF10ULK1
SCHEMBL26811489 0.92 FGFR1 (0.38) FGFR1EGFRKDRF10ULK1
SCHEMBL29567325 0.91 FGFR1 (0.39) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL24309822 0.91 FGFR1 (0.39) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL29567228 0.87 HTR1A (0.40) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL24309861 0.87 HTR1A (0.40) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL29566629 0.86 GPR119 (0.40) HTR1AHTR7
SCHEMBL26808782 0.86 GPR119 (0.40) HTR1AHTR7
SCHEMBL24309774 0.86 HTR1A (0.34) FGFR1EGFRKDRFGFR3PTK2
SCHEMBL29566573 0.86 HTR1A (0.34) FGFR1EGFRKDRFGFR3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback